These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 11899391)

  • 21. Similar contributions of BRCA1 and BRCA2 germline mutations to early-onset breast cancer in Germany.
    Hamann U; Liu X; Bungardt N; Ulmer HU; Bastert G; Sinn HP
    Eur J Hum Genet; 2003 Jun; 11(6):464-7. PubMed ID: 12774040
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators.
    Gayther SA; de Foy KA; Harrington P; Pharoah P; Dunsmuir WD; Edwards SM; Gillett C; Ardern-Jones A; Dearnaley DP; Easton DF; Ford D; Shearer RJ; Kirby RS; Dowe AL; Kelly J; Stratton MR; Ponder BA; Barnes D; Eeles RA
    Cancer Res; 2000 Aug; 60(16):4513-8. PubMed ID: 10969800
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Contribution of BRCA1 and BRCA2 to familial ovarian cancer: a gynecologic oncology group study.
    Reedy M; Gallion H; Fowler JM; Kryscio R; Smith SA
    Gynecol Oncol; 2002 May; 85(2):255-9. PubMed ID: 11972384
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
    J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BRCA2 gene mutations in Slovenian male breast cancer patients.
    Besic N; Cernivc B; de Grève J; Lokar K; Krajc M; Novakovic S; Zgajnar J; Teugels E
    Genet Test; 2008 Jun; 12(2):203-9. PubMed ID: 18439106
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations.
    Fackenthal JD; Olopade OI
    Nat Rev Cancer; 2007 Dec; 7(12):937-48. PubMed ID: 18034184
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BRCA1 gene mutations may explain more than 80% of excess number of ovarian cancer cases after breast cancer - a population based study from the Western Sweden Health Care region.
    Einbeigi Z; Enerbäck C; Wallgren A; Nordling M; Karlsson P
    Acta Oncol; 2010 Apr; 49(3):361-7. PubMed ID: 20151938
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Frequency of the ATM IVS10-6T-->G variant in Australian multiple-case breast cancer families.
    Lindeman GJ; Hiew M; Visvader JE; Leary J; Field M; Gaff CL; Gardner RJ; Trainor K; Cheetham G; Suthers G; Kirk J
    Breast Cancer Res; 2004; 6(4):R401-7. PubMed ID: 15217508
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Contribution of BRCA1 and BRCA2 germ-line mutations to the incidence of breast cancer in young women: results from a prospective population-based study in France.
    Bonadona V; Sinilnikova OM; Chopin S; Antoniou AC; Mignotte H; Mathevet P; Brémond A; Martin A; Bobin JY; Romestaing P; Raudrant D; Rudigoz RC; Léoné M; Chauvin F; Easton DF; Lenoir GM; Lasset C
    Genes Chromosomes Cancer; 2005 Aug; 43(4):404-13. PubMed ID: 15887246
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence of BRCA1/2 mutations in sporadic breast/ovarian cancer patients and identification of a novel de novo BRCA1 mutation in a patient diagnosed with late onset breast and ovarian cancer: implications for genetic testing.
    De Leeneer K; Coene I; Crombez B; Simkens J; Van den Broecke R; Bols A; Stragier B; Vanhoutte I; De Paepe A; Poppe B; Claes K
    Breast Cancer Res Treat; 2012 Feb; 132(1):87-95. PubMed ID: 21553119
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PALB2 analysis in BRCA2-like families.
    Adank MA; van Mil SE; Gille JJ; Waisfisz Q; Meijers-Heijboer H
    Breast Cancer Res Treat; 2011 Jun; 127(2):357-62. PubMed ID: 20582465
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects.
    Díez O; Osorio A; Durán M; Martinez-Ferrandis JI; de la Hoya M; Salazar R; Vega A; Campos B; Rodríguez-López R; Velasco E; Chaves J; Díaz-Rubio E; Jesús Cruz J; Torres M; Esteban E; Cervantes A; Alonso C; San Román JM; González-Sarmiento R; Miner C; Carracedo A; Eugenia Armengod M; Caldés T; Benítez J; Baiget M
    Hum Mutat; 2003 Oct; 22(4):301-12. PubMed ID: 12955716
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does family history predict the age at onset of new breast cancers in BRCA1 and BRCA2 mutation-positive families?
    Panchal S; Bordeleau L; Poll A; Llacuachaqui M; Shachar O; Ainsworth P; Armel S; Eisen A; Sun P; Narod SA
    Clin Genet; 2010 Mar; 77(3):273-9. PubMed ID: 20002453
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of germline BRCA1 and BRCA2 genetic alterations in Greek breast cancer moderate-risk and low-risk individuals--correlation with clinicopathological data.
    Kataki A; Gomatos I; Pararas N; Armakolas A; Panousopoulos D; Karantzikos G; Voros D; Zografos G; Markopoulos C; Leandros E; Konstadoulakis M
    Clin Genet; 2005 Apr; 67(4):322-9. PubMed ID: 15733268
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Are medullary breast cancers an indication for BRCA1 mutation screening? A mutation analysis of 42 cases of medullary breast cancer.
    Iau PT; Marafie M; Ali A; Sng JH; Macmillan RD; Pinder S; Denley HE; Ellis IO; Wenzyck P; Scott N; Cross G; Blamey RW
    Breast Cancer Res Treat; 2004 May; 85(1):81-8. PubMed ID: 15039599
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.
    Berry DA; Iversen ES; Gudbjartsson DF; Hiller EH; Garber JE; Peshkin BN; Lerman C; Watson P; Lynch HT; Hilsenbeck SG; Rubinstein WS; Hughes KS; Parmigiani G
    J Clin Oncol; 2002 Jun; 20(11):2701-12. PubMed ID: 12039933
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Genetic counselling in male carriers of BRCA1 and BRCA2 gene mutations].
    Plevová P; Hladíková A
    Klin Onkol; 2012; 25 Suppl():S67-73. PubMed ID: 22920210
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A follow-up study on men tested for BRCA1/BRCA2 mutations: impacts and coping processes.
    Shiloh S; Dagan E; Friedman I; Blank N; Friedman E
    Psychooncology; 2013 Feb; 22(2):417-25. PubMed ID: 22135240
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Large genomic rearrangement in BRCA1 and BRCA2 and clinical characteristics of men with breast cancer in the United States.
    Tchou J; Ward MR; Volpe P; Palma MD; Medina CA; Sargen M; Sonnad SS; Godwin AK; Daly M; Winchester DJ; Garber J; Weber BL; Domchek S; Nathanson KL
    Clin Breast Cancer; 2007 Jun; 7(8):627-33. PubMed ID: 17592676
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and pathologic characteristics of BRCA-positive and BRCA-negative male breast cancer patients: results from a collaborative multicenter study in Italy.
    Ottini L; Silvestri V; Rizzolo P; Falchetti M; Zanna I; Saieva C; Masala G; Bianchi S; Manoukian S; Barile M; Peterlongo P; Varesco L; Tommasi S; Russo A; Giannini G; Cortesi L; Viel A; Montagna M; Radice P; Palli D
    Breast Cancer Res Treat; 2012 Jul; 134(1):411-8. PubMed ID: 22527108
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.